Silo Pharma (SILO) Other Non-Current Assets (2020 - 2025)
Silo Pharma (SILO) posted Other Non-Current Assets of $56226.0 for Q2 2025, up 16.83% sequentially from $48125.0 in Q1 2025, and down 9.41% YoY from $62064.0 in Q2 2024.
Silo Pharma (SILO) Other Non-Current Assets (2020 - 2025) Analysis & Trends
Silo Pharma has reported Other Non-Current Assets for 6 years, with the latest figure at $56226.0 in Q2 2025.
- Quarterly Other Non-Current Assets fell 9.41% year-over-year to $56226.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $56226.0 (down 9.41% YoY) and the FY2024 annual result came in at $59145.0, down 8.98% from the prior year.
- Other Non-Current Assets rose to $56226.0 in Q2 2025 per SILO's latest filing, from $48125.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $72285.0 in Q3 2022 and troughed at $19375.0 in Q1 2021.
- A 5-year average of $55179.2 and a median of $61334.0 in 2024 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2025: Other Non-Current Assets jumped 222.03% in 2022, then fell 24.24% in 2025.
- Over 5 years, Other Non-Current Assets stood at $26659.0 in 2021, then jumped by 165.66% to $70821.0 in 2022, then retreated by 8.24% to $64983.0 in 2023, then slipped by 8.98% to $59145.0 in 2024, then dropped by 4.94% to $56226.0 in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $56226.0, $48125.0, and $59145.0 for Q2 2025, Q1 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Silo Pharma | 2.92 Mn | 2.92 Mn | - | 26,997.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 56,226.00 |
| Mar 31, 2025 | 48,125.00 |
| Dec 31, 2024 | 59,145.00 |
| Sep 30, 2024 | 60,604.00 |
| Jun 30, 2024 | 62,064.00 |
| Mar 31, 2024 | 63,523.00 |
| Dec 31, 2023 | 64,983.00 |
| Sep 30, 2023 | 66,442.00 |
| Jun 30, 2023 | 67,902.00 |
| Mar 31, 2023 | 69,361.00 |
| Dec 31, 2022 | 70,821.00 |
| Sep 30, 2022 | 72,285.00 |
| Jun 30, 2022 | 33,740.00 |
| Mar 31, 2022 | 62,394.00 |
| Dec 31, 2021 | 26,659.00 |
| Sep 30, 2021 | 60,000.00 |
| Jun 30, 2021 | 29,577.00 |
| Mar 31, 2021 | 19,375.00 |
| Dec 31, 2020 | 33,484.00 |